Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. How we score this
21 firms currently rating it, weighted by track record.
The 20 firms with a track record here beat the S&P 41% of the time over 12 months.
Pro: see the crowd-vs-sharp split for LLYAnalysts rate LLY Buy with a consensus price target of $1324.87, implying 16.4% upside from $1138.28. The most recent rating action came on September 10 when HSBC downgraded to Reduce, breaking a multi-month streak of maintained buy-equivalent ratings. The pharma giant is growing revenue 47.7% year-over-year and earnings per share 26.2% with an exceptional 102.3% return on equity, though it trades at a 38.21 trailing P/E amid a 1.62 debt-to-equity ratio. Multiple insiders have sold shares in the past two months at prices near current levels.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 10, 2026 | HSBC | ○ Maintained | |
| Aug 7, 2026 | Truist Securities | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free